Evolution of the Average Target: Alumis Inc.

Evolution of the Target Price: Alumis Inc.

Changes in Analyst Recommendations: Alumis Inc.

c1585a9ba9fdceb79.MBy1yfeMzCssuWl0RgtoparqJVUHFfSkQhIJVD8Aoxg.UkqMn8bh9FlGjh8dE0g-5Jm-aw1DJZadFE09bH1u5FB9a5i_tPa8YX3AJA~2d60e32ccab4afeac0adf6b3f008675c
09-03 Guggenheim Downgrades Alumis to Neutral From Buy MT
09-02 Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says MT
09-02 Oppenheimer Adjusts Price Target on Alumis to $37 From $55, Maintains Outperform Rating MT
09-02 HC Wainwright Upgrades Alumis to Buy From Neutral, Adjusts Price Target to $15 From $25 MT
05-19 Chardan Raises Price Target on Alumis to $40 From $38, Keeps Buy Rating MT
05-15 HC Wainwright Downgrades Alumis to Neutral From Buy MT
03-30 Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says MT
03-30 Oppenheimer Adjusts Alumis Price Target to $55 From $50, Maintains Outperform Rating MT
03-11 Raymond James Initiates Alumis at Strong Buy With $46 Price Target MT
02-25 Stifel Initiates Alumis at Buy With $44 Price Target MT
01-21 Chardan Initiates Alumis at Buy With $37 Price Target MT
25-07-25 Wells Fargo Initiates Alumis at Overweight With $17 Price Target MT
25-05-15 Oppenheimer Trims Price Target on Alumis to $25 From $26, Keeps Outperform Rating MT
25-02-10 Oppenheimer Adjusts Price Target on Alumis to $26 From $32, Keeps Outperform Rating MT
25-01-30 Oppenheimer Initiates Coverage on Alumis With Outperform Rating, $32 Price Target MT
24-10-31 Baird Initiates Alumis at Outperform With $25 Price Target MT
24-10-17 HC Wainwright Initiates Coverage on Alumis With Buy Rating, $30 Price Target MT
24-07-23 Cantor Fitzgerald Initiates Alumis at Overweight MT
24-07-23 Guggenheim Initiates Alumis at Buy With $32 Price Target MT
24-07-23 Morgan Stanley Initiates Alumis at Overweight With $36 Price Target MT
24-07-23 Leerink Partners Initiates Alumis at Outperform With $29 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+296.12%
+11.45%
+20.14%
+65.16%
+17.73%
+1.06%
+20.45%
-7.67%
+69.94%
+30.69%
Average +52.51%
Weighted average by Cap. +23.11%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
7.440USD
Average target price
32.12USD
Spread / Average Target
+331.79%
High Price Target
46.00USD
Spread / Highest target
+518.28%
Low Price Target
15.00USD
Spread / Lowest Target
+101.61%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ALMS Stock
  4. Consensus Alumis Inc.